Form 4: IO Biotech Director Glaub Acquires Stock Options

Kathleen Sereda Glaub, a director of IO Biotech, Inc., acquired 45,642 stock options on June 6, 2024, exercisable at $1.25.

Summary

• Kathleen Sereda Glaub, a director of IO Biotech, Inc., filed a Form 4 on June 7, 2024, reporting a transaction.
• On June 6, 2024, Glaub acquired 45,642 stock options with an exercise price of $1.25.
• These options vest on June 6, 2025, contingent upon continued service and are subject to full acceleration upon a change of control.
• Following the transaction, Glaub directly owns 45,642 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither particularly positive nor negative on its own.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions and provides insight into the compensation structure and equity ownership of IO Biotech's directors. It's common for directors to receive stock options as part of their compensation.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also grant stock options to their directors as part of their compensation packages.
• The vesting schedules and exercise prices are typically structured to align the interests of the directors with those of the shareholders.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates